A game-theoretic framework for estimating a health purchaser's willingness-to-pay for health and for expansion

Health Care Management Science

Volumn 13, Issue 4, 2010, Pages 358-377

  Yaesoubi, Reza ^a   Roberts, Stephen D ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b North Carolina State University   (United States)

Author keywords

Asymmetric information; Colorectal cancer; Game theory; Health care; Implementation; Moral hazard; Resource allocation; Willingness to pay

Indexed keywords

ARTICLE; COLORECTAL TUMOR; ECONOMICS; FINANCIAL MANAGEMENT; GAME; HEALTH SERVICE; HUMAN; PATIENT ATTITUDE; RESOURCE ALLOCATION;

COLORECTAL NEOPLASMS; FINANCING, PERSONAL; GAME THEORY; HEALTH SERVICES; HUMANS; PATIENT ACCEPTANCE OF HEALTH CARE; RESOURCE ALLOCATION;

EID: 78049289839     PISSN: 13869620     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10729-010-9135-6     Document Type: Article

References (45)

1. American Cancer Society (2007) Cancer prevention & early detection facts & figures. American Cancer Society, Atlanta.
2. Bayoumi AM, Redelmeier DA (2000) Decision analysis with cumulative prospect theory. Med Decis Mak 20: 404-412.
3. Blomqvist A (1997) Optimal non-linear health insurance. J Health Econ 16: 303-321.
4. Byrne MM, O'Malley K, Suarez-Almazor ME (2005) Willingness to pay per quality-adjusted life year in a study of knee osteoarthritis. Med Decis Mak 25: 655-666.
5. Centers for Disease Control and Prevention (2008) Colorectal (colon) cancer. Available via http://www. cdc. gov/cancer/colorectal/basic_info/index. htm. Accessed 1 May 2010.
6. Centers for Disease Control and Prevention (2010) Colorectal (colon) cancer: insurance and medicare. Available via http://www. cdc. gov/cancer/colorectal/basic_info/screening/insurance. htm. Accessed 1 May 2010.
7. Chernew ME, Encinosa WE, Hirth RA (2000) Optimal health insurance: the case of observable, severe illness. J Health Econ 19: 585-609.
8. Cookson R (2003) Willingness to pay methods in health care: a sceptical view. Health Econ 13: 891-894.
9. Diener A, O'Brien B, Gafni A (1998) Health care contingent valuation studies: a review and classification of the literature. Health Econ 7: 313-326.
10. Ellis RP, Manning WG (2007) Optimal health insurance for prevention and treatment. J Health Econ 26: 1128-1150.
11. Frew E, Wolstenholme JL, Whynes DK (2001) Willingness-to-pay for colorectal cancer screening. Eur J Cancer 37: 1746-1751.
12. Gafni A, Birch S (2006) Incremental cost-effectiveness ratios (ICERs): the silence of the lambda. Soc Sci Med 62: 2091-2100.
13. Gibbons R (1992) Game theory for applied economists. Princeton University Press, Princeton.
14. Gold MR, Siegel JE, Russell LB, Weinstein MC (1996) Cost-effectiveness in health and medicine. Oxford University Press, New York.
15. Hammerschmidt T, Zeitler H-P, Leidl R (2004) A utility-theoretic approach to the aggregation of willingness to pay measured in decomposed scenarios: development and empirical test. Health Econ 13: 345-361.
16. Harvard School of Public Health (2008) Tools and strategies to increase colorectal cancer screening rates: a practical guide for health insurance plans.
17. Hirth RA, Chernew ME, Miller E, Fendrick AM, Weissert WG (2000) Willingness to pay for a quality-adjusted life year: in search of a standard. Med Decis Mak 20: 332-342.
18. Jonas DE, Russell LB, Sandler RS, Chou J, Pignone M (2008) Value of patient time invested in the colonoscopy screening process: time requirements for colonoscopy study. Med Decis Mak 28: 56-65.
19. Kahneman D, Tversky A (1979) Prospect theory: an analysis of decision under risk. Econometrica 47: 263-291.
20. Keeney RL, Raiffa H (1993) Decisions with multiple objectives: preferences and value tradeoffs. Cambridge University Press, New York.
21. King JT, Tsevat J, Lave JR, Roberts MR (2005) Willingness to pay for a quality-adjusted life year: implications for societal health care resource allocation. Med Decis Mak 25: 667-677.
22. Klose T (2003) A utility-theoreticmodel for QALYs and willingness to pay. Health Econ 12: 17-31.
23. Laffont J-J, Martimort D (2001) The theory of incentives: the principal-agent model. Princeton University Press.
24. Lee CP, Zenios SA (2008) A shadow price framework for quantifying health care demand, spending and disparity. OPIM Department Working paper, The Wharton School.
25. Levin B, Lieberman DA, McFarland B, Andrews KS, Brooks D, Bond J, Dash C, Giardiello FM, Glick S, Johnson D et al (2008) Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. Gastroenterology 134(5): 1570-1595.
26. Lewis JD, Asch DA (1999) Barriers to office-based screening sigmoidoscopy: does reimbursement cover costs? Ann Intern Med 130: 525-530.
27. Miyamoto JM, Wakker PP, Bleichrodt H, Peters HJM (1998) The zero-condition: a simplifying assumption in QALY measurement and multiattribute utility. Manage Sci 44: 839-849.
28. Mooney G, Ryan M (1993) Agency in health care: getting beyond first principles. J Health Econ 12: 125-135.
29. National Cancer Institute (2007) Cancer trends progress report. Available via http://progressreport. cancer. gov/trends-glance. asp. Accessed 1 May 2010.
30. Pauly MV, Held PJ (1990) Benign moral hazard and the cost-effectiveness analysis of insurance coverage. J Health Econ 9: 447-461.
31. Pignone M, Bucholtz D, Harris R (1999) Patient preferences for colorectal cancer screening. J Gen Intern Med 14: 432-437.
32. Pignone M, Rich M, Teutsch SM, Berg AO, Lohr KN (2002) Screening for colorectal cancer in adults at average risk: a summary of the evidence for the US preventive services task force. Ann Intern Med 137: 132-141.
33. Pliskin JS, Shepard DS, Weinstein MC (1980) Utility functions for life years and health status. Oper Res 28: 206-224.
34. Polsky D (2005) Does willingness to pay per quality-adjusted life year bring us closer to a useful decision rule for cost-effectiveness analysis? Med Decis Mak 25: 605-606.
35. Roberts SD, Wang L, Klein RL, Ness RM, Dittus RS (2007) Development of a simulation model of colorectal cancer. ACM Trans Model Comput Simul (TOMACS) 18: 4: 1-4: 30.
36. Seror V (2008) Fitting observed and theoretical choices-women's choices about prenatal diagnosis of Down syndrome. Health Econ 17: 557-577.
37. Shaheen NJ, Ransohoff DF (1999) Sigmoidoscopy costs and the limits of altruism. Am J Med 107: 286-287.
38. Simon CP, Blume L (1994) Mathematics for economists. Norton, New York.
39. Smith JE, Keeney RL (2005) Your money or your life: a prescriptive model for health, safety, and consumption decisions. Manage Sci 51: 1309-1325.
40. Smith RA, Cokkinides V, Brawley OW (2008) Cancer screening in the United States, 2008: a review of current American Cancer Society guidelines and cancer screening issues. CA (Cancer Journal for Clinicians) 58: 161-179.
41. Swan J, Breen N, Coates RJ, Rimer BK, Lee NC (2003) Progress in cancer screening practices in the United States: results from the 2000 national health interview survey. Cancer 97: 1528-1540.
42. Tafazzoli A, Roberts SD, Ness RM, Klein RW, Dittus RS (2009) Probabilistic cost-effectiveness comparison of screening strategies for colorectal cancer. ACM Trans Model Comput Simul 9(2): 6: 1-6: 29.
43. Tversky A, Kahneman D (1992) Advances in prospect theory: cumulative representation of uncertainty. J Risk Uncertain 5: 297-323.
44. Ward E, Halpern M, Schrag N, Cokkinides V et al (2008) Association of insurance with cancer care utilization and outcomes. CA (Cancer Journal for Clinicians) 58: 9-31.
45. Zank H (2001) Cumulative prospect theory for parametric and multiattribute utilities. Math Oper Res 26: 67-81.